Do you want to read an article? Please log in or register.
Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis
Inflammatory Bowel Disease
Related content
COMMENTED
Inflammatory Bowel Disease
Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis
Inflamm Bowel Dis.
Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS
doi: 10.1093/ibd/izy307.
Inflammatory Bowel Disease
Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients
J Crohns Colitis.
Cushing KC, Kordbacheh H, Gee MS, Kambadakone A, Ananthakrishnan AN
doi: 10.1093/ecco-jcc/jjy064.
Inflammatory Bowel Disease
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
N Engl J Med.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C, UNIFI Study Group.
doi: 10.1056/NEJMoa1900750.
RECOMMENDED
Inflammatory Bowel Disease
Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Kotwani P, Terdiman J, Lewin S
doi: 10.1093/ecco-jcc/jjaa018.
Inflammatory Bowel Disease
A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials
J Crohns Colitis.
Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-Biroulet L, Brodmerkel C, De Hertogh G
doi: 10.1093/ecco-jcc/jjz022.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Am J Gastroenterol.
Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS
doi: 10.1038/s41395-018-0162-0.
Inflammatory Bowel Disease
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Clin Gastroenterol Hepatol.
Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV Jr, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C
doi: 10.1016/j.cgh.2020.02.010.
Inflammatory Bowel Disease
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study
United European Gastroenterol J
Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C
doi: 10.1177/2050640620977405
Inflammatory Bowel Disease
Cannabis for the treatment of ulcerative colitis
Cochrane Database Syst Rev.
Kafil TS, Nguyen TM, MacDonald JK, Chande N
doi: 10.1002/14651858.